Human Insulin Market Size, Industry Shares, Global Growth And Analysis

The International Diabetes Federation (IDF) estimates that approximately 463 million adults within the age group of 20–79 years were living with diabetes in 2019, and the number is expected to rise to 700 million by 2045. This disease caused around 4.2 million deaths in 2019. As per the IDF, more than 1.1 million adolescents and children are currently living with type 1 diabetes. What is worse is that at present, around 374 million people are at an increased risk of developing type 2 diabetes. 

In recent years, diabetic patients have been showing a higher preference for the different variants of the artificially produced hormone than delivery devices due to the extensive research by pharmaceutical companies in drug discovery and development. Essentially, devices, once bought, last years, while the insulin vials and cartridges empty with regular use, prompting people to replenish their stock regularly. Premixed, long-acting, and rapid-acting HI analogs and short-acting, intermediate/rapid-acting, and premixed HI biologics are available for diabetes management. 

Human Insulin Market

To download a free sample copy of this report@ https://www.psmarketresearch.com/market-analysis/human-insulin-market/report-sample

These products are manufactured by Gulf Pharmaceutical Industries (Julphar), Novo Nordisk A/S, Ypsomed AG, Wockhardt Ltd., Becton, Dickinson and Company, B. Braun Melsungen AG, Eli Lilly and Company, and Medtronic PLC. At present, these companies are focusing on product launches to offer new and improved HI variants and delivery devices to their existing and potential customers. For instance, Sanofi obtained the U.S. Food and Drug Administration (USFDA) approval for Admelog (insulin lispro injection) in December 2017. It is a rapid-acting insulin that enables people to manage their blood glucose levels at mealtime. 

Globally, the North American region consumed the largest volume of HI and bought the highest number of delivery devices in the preceding years due to the escalating healthcare expenditure, burgeoning cases of diabetes, and increasing research and development (R&D) activities in the area of biosimilars. According to the National Diabetes Statistics Report 2020 by the Centers for Disease Control and Prevention (CDC), 34.2 million people in the U.S. suffer from diabetes. Out of this, nearly 26.9 million cases are diagnosed, whereas 7.3 million cases remain undiagnosed. 

Whereas, the Asia-Pacific (APAC) human insulin market is expected to advance at the highest rate in the upcoming years. This will be due to the rising incidence of diabetes and soaring geriatric population in India and China. For instance, the IDF forecasts that the number of diabetes patients in India within the age group of 20–79 years will surge from 77,005,600 in 2019 to 100,956,400 in 2030 and 134,239,300 in 2045. Essentially, the shift toward an unhealthy lifestyle owing to the rapid urbanization will propel the adoption of insulin and delivery devices in the region. 

Therefore, the rising cases of diabetes owing to an unhealthy lifestyle will fuel the adoption of HI and delivery devices. 

SOURCE: P&S Intelligence